The Diagnostic Value of MR Imaging in Determining the Lymph Node Status of Patients with Non–Small Cell Lung Cancer: A Meta-Analysis

Peerlings, Jurgen; Troost, Esther G.C.; Nelemans, Patricia J.; Cobben, D.; Boer, J.C.J. de; Hoffmann, Aswin L.; Beets‐Tan, Regina G. H.

doi:10.1148/radiol.2016151631

Cited by 42 publications

(37 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This serum-based approach is advantageous than biopsy, an invasive procedure that serves as the main tool for lung cancer risk assessment. In addition, this serum-based miR-96 biomarker may even serve as an alternative to other imaging modalities, such as computed tomography and magnetic resonance imaging, the clinical utility of which is impaired by their high cost and ineffectiveness to determine lung cancer risk [19][20][21][22]. Our results concur with previous studies showing that other miRNA families, such as the miR-200 family, within circulating exosomes possess both diagnostic and prognostic relevance in patients with epithelial ovarian cancer [23].…”

Section: Discussionmentioning

confidence: 99%

Circulating exosomal microRNA‐96 promotes cell proliferation, migration and drug resistance by targeting LMO7

Zhou

Mei

et al. 2016

J Cellular Molecular Medi

144

View full text Add to dashboard Cite

Detection and treatment of lung cancer still remain a clinical challenge. This study aims to validate exosomal microRNA‐96 (miR‐96) as a serum biomarker for lung cancer and understand the underlying mechanism in lung cancer progression. MiR‐96 expressions in normal and lung cancer patients were characterized by qPCR analysis. Changes in cell viability, migration and cisplatin resistance were monitored after incubation with isolated miR‐96‐containing exosomes, anti‐miR‐96 and anti‐miR negative control (anti‐miR‐NC) transfections. Dual‐luciferase reporter assay was used to study interaction between miR‐96 and LIM‐domain only protein 7 (LMO7). Changes induced by miR‐96 transfection and LMO7 overexpression were also evaluated. MiR‐96 expression was positively correlated with high‐grade and metastatic lung cancers. While anti‐miR‐96 transfection exhibited a tumour‐suppressing function, exosomes isolated from H1299 enhanced cell viability, migration and cisplatin resistance. Potential miR‐96 binding sites were found within the 3′‐UTR of wild‐type LMO7 gene, but not of mutant LMO7 gene. LMO7 expression was inversely correlated with lung cancer grades, and LMO7 overexpression reversed promoting effect of miR‐96. We have identified exosomal miR‐96 as a serum biomarker of malignant lung cancer. MiR‐96 promotes lung cancer progression by targeting LMO7. The miR‐96‐LMO7 axis may be a therapeutic target for lung cancer patients, and new diagnostic or therapeutic strategies could be developed by targeting the miR‐96‐LMO7 axis.

show abstract

Section: Discussionmentioning

confidence: 99%

Circulating exosomal microRNA‐96 promotes cell proliferation, migration and drug resistance by targeting LMO7

Zhou

Mei

et al. 2016

J Cellular Molecular Medi

144

View full text Add to dashboard Cite

show abstract

“…25) Recently, the diagnostic capability of MRI has developed and two articles of meta-analysis reported that DWI was effective for the evaluation of N factor of lung cancer. 26,27) Meta-analysis of the MRI by Peerlings et al 26) revealed high diagnostic capability that the sensitivity was 0.87, the specificity 0.88 for nodal assessment in the non-small-cell lung cancer.…”

Section: Resultsmentioning

confidence: 99%

Economic Benefits and Diagnostic Quality of Diffusion-Weighted Magnetic Resonance Imaging for Primary Lung Cancer

Usuda

Funazaki

Maeda

et al. 2017

ATCS

View full text Add to dashboard Cite

IntroductionThis paper focuses on the latest research of diffusion-weighted magnetic resonance imaging (DWI), and deals with economic benefits, diagnostic benefits, and prospects of DWI for lung cancer. The medical cost of a magnetic resonance imaging (MRI) is 81%-84% cheaper than that of 18-fluoro-2-deoxy-glucose positron emission tomography/computed tomography (FDG-PET/CT). DWI is reported to be useful for differential diagnosis of malignancy or benignity for neoplasm in various organs. Diagnostic efficacy by DWI for pulmonary nodules and masses and the evaluation of N factor and M factor in lung cancer are equivalent to or more than that of FDG-PET/CT. The diagnostic capability of wholebody DWI (WB-DWI) for the staging of clinically operable lung cancers is equivalent to that of FDG-PET/CT and brain MRI, and WB-DWI is now becoming a more main stream procedure. Although the diagnostic performance of DWI for lung cancer may be equivalent to that of FDG-PET/CT, prospective randomized controlled trial for comparison of diagnostic efficacy between FDG-PET/CT and DWI for lung cancer is necessary for an accurate comparison. DWI may have an advantage in the aspect of the cost and diagnostic efficacy in lung cancer management.

show abstract

“…[9][10][11][12][13][14][15][16][17][18][19][20] Many have combined multiple cancer types in one single meta-analysis. [9][10][11]13,14,16,17 Those meta-analyses considering the staging of only lung cancer have limited themselves to the detection of bone 12,15 or nodal [18][19][20] metastasis. No meta-analysis has considered colon cancer in isolation, and the largest study to date recruited just 20 participants.…”

Section: Existing Literature On the Diagnostic Accuracy Of Wb-mri In mentioning

confidence: 99%

Whole-body MRI compared with standard pathways for staging metastatic disease in lung and colorectal cancer: the Streamline diagnostic accuracy studies

Taylor

Mallett

Miles

et al. 2019

Health Technol Assess

View full text Add to dashboard Cite

Background Whole-body magnetic resonance imaging is advocated as an alternative to standard pathways for staging cancer. Objectives The objectives were to compare diagnostic accuracy, efficiency, patient acceptability, observer variability and cost-effectiveness of whole-body magnetic resonance imaging and standard pathways in staging newly diagnosed non-small-cell lung cancer (Streamline L) and colorectal cancer (Streamline C). Design The design was a prospective multicentre cohort study. Setting The setting was 16 NHS hospitals. Participants Consecutive patients aged ≥ 18 years with histologically proven or suspected colorectal (Streamline C) or non-small-cell lung cancer (Streamline L). Interventions Whole-body magnetic resonance imaging. Standard staging investigations (e.g. computed tomography and positron emission tomography–computed tomography). Reference standard Consensus panel decision using 12-month follow-up data. Main outcome measures The primary outcome was per-patient sensitivity difference between whole-body magnetic resonance imaging and standard staging pathways for metastasis. Secondary outcomes included differences in specificity, the nature of the first major treatment decision, time and number of tests to complete staging, patient experience and cost-effectiveness. Results Streamline C – 299 participants were included. Per-patient sensitivity for metastatic disease was 67% (95% confidence interval 56% to 78%) and 63% (95% confidence interval 51% to 74%) for whole-body magnetic resonance imaging and standard pathways, respectively, a difference in sensitivity of 4% (95% confidence interval –5% to 13%; p = 0.51). Specificity was 95% (95% confidence interval 92% to 97%) and 93% (95% confidence interval 90% to 96%) respectively, a difference of 2% (95% confidence interval –2% to 6%). Pathway treatment decisions agreed with the multidisciplinary team treatment decision in 96% and 95% of cases, respectively, a difference of 1% (95% confidence interval –2% to 4%). Time for staging was 8 days (95% confidence interval 6 to 9 days) and 13 days (95% confidence interval 11 to 15 days) for whole-body magnetic resonance imaging and standard pathways, respectively, a difference of 5 days (95% confidence interval 3 to 7 days). The whole-body magnetic resonance imaging pathway was cheaper than the standard staging pathway: £216 (95% confidence interval £211 to £221) versus £285 (95% confidence interval £260 to £310). Streamline L – 187 participants were included. Per-patient sensitivity for metastatic disease was 50% (95% confidence interval 37% to 63%) and 54% (95% confidence interval 41% to 67%) for whole-body magnetic resonance imaging and standard pathways, respectively, a difference in sensitivity of 4% (95% confidence interval –7% to 15%; p = 0.73). Specificity was 93% (95% confidence interval 88% to 96%) and 95% (95% confidence interval 91% to 98%), respectively, a difference of 2% (95% confidence interval –2% to 7%). Pathway treatment decisions agreed with the multidisciplinary team treatment decision in 98% and 99% of cases, respectively, a difference of 1% (95% confidence interval –2% to 4%). Time for staging was 13 days (95% confidence interval 12 to 14 days) and 19 days (95% confidence interval 17 to 21 days) for whole-body magnetic resonance imaging and standard pathways, respectively, a difference of 6 days (95% confidence interval 4 to 8 days). The whole-body magnetic resonance imaging pathway was cheaper than the standard staging pathway: £317 (95% confidence interval £273 to £361) versus £620 (95% confidence interval £574 to £666). Participants generally found whole-body magnetic resonance imaging more burdensome than standard imaging but most participants preferred the whole-body magnetic resonance imaging staging pathway if it reduced time to staging and/or number of tests. Limitations Whole-body magnetic resonance imaging was interpreted by practitioners blinded to other clinical data, which may not fully reflect how it is used in clinical practice. Conclusions In colorectal and non-small-cell lung cancer, the whole-body magnetic resonance imaging staging pathway has similar accuracy to standard staging pathways, is generally preferred by patients, improves staging efficiency and has lower staging costs. Future work should address the utility of whole-body magnetic resonance imaging for treatment response assessment. Trial registration Current Controlled Trials ISRCTN43958015 and ISRCTN50436483. Funding This project was funded by the NIHR Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 23, No. 66. See the NIHR Journals Library website for further project information.

show abstract

The Diagnostic Value of MR Imaging in Determining the Lymph Node Status of Patients with Non–Small Cell Lung Cancer: A Meta-Analysis

Cited by 42 publications

References 79 publications

Circulating exosomal microRNA‐96 promotes cell proliferation, migration and drug resistance by targeting LMO7

Circulating exosomal microRNA‐96 promotes cell proliferation, migration and drug resistance by targeting LMO7

Economic Benefits and Diagnostic Quality of Diffusion-Weighted Magnetic Resonance Imaging for Primary Lung Cancer

Whole-body MRI compared with standard pathways for staging metastatic disease in lung and colorectal cancer: the Streamline diagnostic accuracy studies

Contact Info

Product

Resources

About